JP2015505564A - 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 - Google Patents

第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 Download PDF

Info

Publication number
JP2015505564A
JP2015505564A JP2014555758A JP2014555758A JP2015505564A JP 2015505564 A JP2015505564 A JP 2015505564A JP 2014555758 A JP2014555758 A JP 2014555758A JP 2014555758 A JP2014555758 A JP 2014555758A JP 2015505564 A JP2015505564 A JP 2015505564A
Authority
JP
Japan
Prior art keywords
laquinimod
disease
crohn
patient
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014555758A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505564A5 (enExample
Inventor
タルシック、ノラ
ハヴィブ、アシ
ブラウグルンド、エラン
ケイ、ジョエル
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド, テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2015505564A publication Critical patent/JP2015505564A/ja
Publication of JP2015505564A5 publication Critical patent/JP2015505564A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2014555758A 2012-02-03 2013-02-01 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用 Withdrawn JP2015505564A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261595006P 2012-02-03 2012-02-03
US61/595,006 2012-02-03
PCT/US2013/024356 WO2013116657A1 (en) 2012-02-03 2013-02-01 USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017104049A Division JP2017200926A (ja) 2012-02-03 2017-05-26 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用

Publications (2)

Publication Number Publication Date
JP2015505564A true JP2015505564A (ja) 2015-02-23
JP2015505564A5 JP2015505564A5 (enExample) 2016-03-10

Family

ID=48903432

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014555758A Withdrawn JP2015505564A (ja) 2012-02-03 2013-02-01 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
JP2017104049A Withdrawn JP2017200926A (ja) 2012-02-03 2017-05-26 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017104049A Withdrawn JP2017200926A (ja) 2012-02-03 2017-05-26 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用

Country Status (16)

Country Link
US (3) US9161935B2 (enExample)
EP (1) EP2811832A4 (enExample)
JP (2) JP2015505564A (enExample)
KR (1) KR20140138694A (enExample)
CN (2) CN104093310A (enExample)
AR (1) AR089862A1 (enExample)
AU (2) AU2013214909A1 (enExample)
BR (1) BR112014018485A8 (enExample)
CA (1) CA2862865A1 (enExample)
EA (1) EA201491460A1 (enExample)
HK (1) HK1202776A1 (enExample)
IL (1) IL233557A0 (enExample)
MX (1) MX2014009373A (enExample)
SG (1) SG11201404214QA (enExample)
TW (1) TW201345527A (enExample)
WO (1) WO2013116657A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021170017A (ja) * 2015-09-17 2021-10-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
CA2786994C (en) 2010-01-27 2018-01-16 Arena Pharmaceuticals, Inc. Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
EP2970129A2 (en) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
EP3094330A4 (en) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Treatment of crohn's disease using low doses of laquinimod
KR20170005434A (ko) 2014-04-29 2017-01-13 테바 파마슈티컬 인더스트리즈 리미티드 높은 장애 상태를 갖는 재발-완화형 다발성 경화증(rrms) 환자 치료용 라퀴니모드
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
JP2020507610A (ja) 2017-02-16 2020-03-12 アリーナ ファーマシューティカルズ， インコーポレイテッド 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
AU2019387212A1 (en) * 2018-11-30 2021-06-24 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002513006A (ja) * 1998-04-27 2002-05-08 アクティブ バイオテック エイビー キノリン誘導体
WO2011014255A1 (en) * 2009-07-30 2011-02-03 Teva Pharmaceutical Industries Ltd. Treatment of crohn's disease with laquinimod

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3024257A (en) 1961-04-10 1962-03-06 Frosst & Co Charles E Stable preparations of alkali metal salts of estrone sulfate
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
DE3437232A1 (de) 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
US4782155A (en) 1986-03-19 1988-11-01 Banyu Pharmaceutical Co., Ltd. Cephalosporin derivatives, processes for their preparation and antibacterial agents
US5139878A (en) 1991-08-12 1992-08-18 Allied-Signal Inc. Multilayer film constructions
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5912349A (en) 1997-01-31 1999-06-15 Pharmacia & Upjohn Company Process for the preparation of roquinimex
US20030124187A1 (en) 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
US6696407B1 (en) 1997-03-21 2004-02-24 The Regents Of The University Of California Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
GB9726339D0 (en) 1997-12-13 1998-02-11 Zeneca Ltd Human-derived tissue-specific potassium channel
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
PL199781B1 (pl) 1999-10-25 2008-10-31 Active Biotech Ab Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
WO2002007757A2 (en) 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US6307050B1 (en) 2000-08-29 2001-10-23 R. T. Alamo Venture I Llc Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US6802422B2 (en) 2000-12-12 2004-10-12 Multi-Comp, Inc. Sealed blister assembly
US6706733B2 (en) 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US20030119826A1 (en) 2001-09-24 2003-06-26 Pharmacia Corporation Neuroprotective treatment methods using selective iNOS inhibitors
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7560557B2 (en) 2002-06-12 2009-07-14 Active Biotech Ag Process for the manufacture of quinoline derivatives
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
ATE356808T1 (de) 2002-06-25 2007-04-15 Merck Frosst Canada Ltd 8-(biaryl)chinolin-pde4-inhibitoren
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
AU2004251750A1 (en) 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
JP2007531735A (ja) 2004-04-01 2007-11-08 エラン ファーマシューティカルズ，インコーポレイテッド ステロイド節約剤および該節約剤を使用する方法
CA2579038A1 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
DK1797109T3 (en) 2004-09-09 2016-04-11 Yeda Res & Dev MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
JP2008527002A (ja) 2005-01-13 2008-07-24 サートリス ファーマシューティカルズ， インコーポレイテッド 神経変性障害および血液凝固障害を予防および処置するための新規組成物
EP1902034B1 (en) 2005-06-02 2011-03-30 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
SG10201508623RA (en) 2005-10-19 2015-11-27 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
RS52229B (sr) 2005-10-26 2012-10-31 Merck Serono Sa. Derivati sulfonamida i njihova upotreba za modulaciju metaloproteinaza
US20080108641A1 (en) 2006-02-08 2008-05-08 Ajami Alfred M Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en) 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
CA2641160A1 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
HUE047230T2 (hu) * 2006-02-28 2020-04-28 Biogen Ma Inc Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
AU2007224228B2 (en) 2006-03-03 2013-09-19 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2007109052A2 (en) 2006-03-16 2007-09-27 Genentech, Inc. Methods of treating lupus using cd4 antibodies
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
WO2007146331A1 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
KR20150065951A (ko) 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
RU2009105179A (ru) 2006-07-17 2010-08-27 Новартис АГ (CH) Сульфониламинокарбонилпроизводные амидов холевой кислоты для применения в качестве иммуномодуляторов
EP1886996A1 (en) 2006-08-10 2008-02-13 Ferrer Internacional, S.A. 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
EP2056818B1 (en) 2006-08-11 2011-05-25 The Johns Hopkins University Compositions and methods for neuroprotection
WO2008021532A2 (en) 2006-08-17 2008-02-21 University Of Chicago Treatment of inflammatory diseases
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
PT2187882E (pt) 2007-07-11 2013-04-17 Medicinova Inc Tratamento de uma doença neurodegenerativa progressiva com ibudilast
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
WO2009082471A1 (en) 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
ES2329327B1 (es) 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
MX2011002033A (es) 2008-09-03 2011-05-02 Teva Pharma 2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
EP2442651B1 (en) 2009-06-19 2015-07-29 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
CA2771203C (en) 2009-08-10 2019-04-09 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
DE102010026879A1 (de) * 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
WO2011109526A1 (en) 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
US20110217295A1 (en) 2010-03-03 2011-09-08 Asi Haviv Treatment of lupus arthritis using laquinimod
MX2012010066A (es) 2010-03-03 2012-10-03 Teva Pharma Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato.
CN104610144A (zh) 2010-07-09 2015-05-13 泰华制药工业有限公司 氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
EA201390074A1 (ru) 2010-07-09 2013-06-28 Тева Фармасьютикал Индастриз Лтд. 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
CA2820586A1 (en) 2010-12-07 2012-06-14 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
CN103781354A (zh) 2011-07-28 2014-05-07 泰华制药工业有限公司 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
SG10201606204TA (en) 2011-07-28 2016-09-29 Teva Pharma Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
AR090885A1 (es) 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
WO2014004733A1 (en) 2012-06-26 2014-01-03 The Regents Of The University Of California Composition for lupus nephritis and methods of making and using the same
AR091706A1 (es) 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
UY34896A (es) 2012-07-12 2014-02-28 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
TW201410243A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
US20140107154A1 (en) 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
WO2014127139A1 (en) 2013-02-15 2014-08-21 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
MX2015010967A (es) 2013-03-14 2015-10-26 Teva Pharma Formulaciones transdermicas de laquinimod.
EP2970129A2 (en) 2013-03-14 2016-01-20 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
EP3094330A4 (en) * 2014-01-17 2017-09-27 Teva Pharmaceutical Industries Ltd Treatment of crohn's disease using low doses of laquinimod

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002513006A (ja) * 1998-04-27 2002-05-08 アクティブ バイオテック エイビー キノリン誘導体
WO2011014255A1 (en) * 2009-07-30 2011-02-03 Teva Pharmaceutical Industries Ltd. Treatment of crohn's disease with laquinimod

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"View of NCT00737932 on 2012_01_24", CLINICALTRIALS.GOV ARCHIVE, JPN7016003482, 24 January 2012 (2012-01-24), ISSN: 0003445892 *
YANAI, HENIT ET AL: "Assessing response and loss of response to biological therapies in IBD", THE AMERICAN JOURNAL OF GASTROENTERLOGY, vol. 106, no. 4, JPN6016044196, January 2011 (2011-01-01), pages 685 - 698, XP009557206, ISSN: 0003445893, DOI: 10.1038/ajg.2011.103 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021170017A (ja) * 2015-09-17 2021-10-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
JP7153775B2 (ja) 2015-09-17 2022-10-14 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測

Also Published As

Publication number Publication date
US20150359788A1 (en) 2015-12-17
EP2811832A4 (en) 2015-09-23
HK1202776A1 (en) 2015-10-09
IL233557A0 (en) 2014-08-31
AU2013214909A1 (en) 2014-09-18
AR089862A1 (es) 2014-09-24
AU2017200472A1 (en) 2017-02-09
US9161935B2 (en) 2015-10-20
JP2017200926A (ja) 2017-11-09
WO2013116657A1 (en) 2013-08-08
BR112014018485A2 (enExample) 2017-06-20
SG11201404214QA (en) 2014-08-28
KR20140138694A (ko) 2014-12-04
CA2862865A1 (en) 2013-08-08
MX2014009373A (es) 2014-08-27
US20170290822A1 (en) 2017-10-12
TW201345527A (zh) 2013-11-16
CN106063787A (zh) 2016-11-02
EA201491460A1 (ru) 2015-01-30
CN104093310A (zh) 2014-10-08
BR112014018485A8 (pt) 2017-07-11
EP2811832A1 (en) 2014-12-17
US20130203807A1 (en) 2013-08-08

Similar Documents

Publication Publication Date Title
JP2017200926A (ja) 第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
JP5882208B2 (ja) ラキニモドによるクローン病の治療
JP2017165740A (ja) ラキニモドを使用したループス腎炎の治療
US20160331742A1 (en) Treatment of crohn's disease using low doses of laquinimod
HK1226961A (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnfalpha therapy
HK1226961A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnfalpha therapy
HK1224556A1 (en) Treatment of crohn's disease with laquinimod
HK1224556A (zh) 利用拉喹莫德治疗克隆氏病

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170725

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20171031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171101